Psoriazis Tanılı Hastalarda Migren Görülme Sıklığı: Bir Prospektif Çalışma

Öz

Amaç: Bu prospektif çalışmamızdaki amacımız kliniğimize başvuran psoriazis tanılı hastalarda migren görülme sıklığını araştırmaktır.Gereç ve Yöntemler: Çalışmamıza Kasım 2017 ve Mayıs 2018 tarihleri arasında, kliniğimize başvuran ve histopatolojik incelemeyle psoriazis tanısı konulan 163 hasta dahil edildi. Psoriasis Area Severity Index PAŞİ skoru ≤10 olanlar hafif, >10 olanlar ise orta/şiddetli psöriazis olarak değerlendirildi. Dermatology Life Quality Index DLQI ≤10 olanlar hafif, DLQI >10 olanlar orta/şiddetli psöraizis olarak kabul edildi. Nöroloji kliniği tarafından Uluslararası Baş Ağrısı Derneği’nin tanı kriterlerine göre migren tanısı konulan hastalar kaydedildi.Bulgular: Psöriazisli hastalarda migren görülme sıklığı %8.5 olarak saptandı. Migreni olan ve olmayan hastalar hastalık şiddeti ve eklem tutulumu açısından karşılaştırıldığında anlamlı bir fark saptanmadı p değeri sırasıyla=0.43, 0.84 . Migreni olan hastalar PAŞİ ve DLQI’ye göre hafif ve şiddetli olarak sınıflandırıldığında da her iki grup arasında istatistiksel olarak anlamlı bir fark saptanmadı p değeri sırasıyla=0.164, 0.34 .Sonuç: Sonuç olarak yaptığımız çalışmada psoriazis hastalarında migren sıklığı fazla saptanmamışsa da, psoriazise migrenin eşlik edebileceğini ve baş ağrısı olan tüm psoriazis hastalarında erken tanı ve tarama amaçlı nörolojik değerlendirme yapılması gerektiğini düşünmekteyiz

Anahtar Kelimeler

• Aura, Baş ağrısı, Leptin, Migren, Psoriasis

Prevalence of Migraine in Patients with Psoriasis: A Prospective Study

Abstract

Objective: The aim of this prospective study was to investigate the prevalence of migraine in patients with psoriasis.Material and Methods: A total of 163 patients who presented at our clinic between November 2017 and May 2018 and were diagnosed with psoriasis through histopathological examination were included in our study. Patients with Psoriasis Area Severity Index PASI scores ≤10 were considered to have mild psoriasis, and those whose PASI scores were >10 were considered to have moderate/severe psoriasis. Patients with Dermatology Life Quality Index DLQI scores ≤10 were considered mild, while those with DLQI scores >10 considered moderate/severe. Patients diagnosed with migraine by the neurology clinic pursuant to the diagnostic criteria of the International Headache Society were recorded.Results: The prevalence of migraine was found to be 8.5% in patients with psoriasis. No significant difference was found between patients with and without migraine in terms of disease severity and joint involvement p values= 0.43, 0.84, respectively . Patients with migraine were classified into two groups as mild and severe according to PASI and DLQI scores and no statistically significant difference was found between the two groups p values: =0.164, 0.34, respectively .Conclusion: In conclusion, although the prevalence of migraine was not found to be high in psoriasis patients in our study, we suggest that psoriasis may be accompanied by migraine and a neurological examination should be carried out for all psoriasis patients suffering from headache for early diagnosis and screening

Keywords

• Aura, Headache, Leptin, Migraine, Psoriasis

References

1. An I, Ucmak D. Evaluation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and C-reactive protein in patients with psoriasis vulgaris. Dicle Med J 2018; 45:327-34.
2. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the development of psoriasis. Int J Mol Sci 2019; 20(18):4347.
3. An I, Ucmak D, Ozturk M, Aksoy M, Yıldız I, Ucan E. Neutrophil / Iymphocyte ratio, platelet / Iymphocyte ratio, mean platelet volume and C-reactive protein values in psoriatic arthritis patients. Ann Med Res 2019; 26(5):894-8.
4. An İ. Tatuaj komplikasyonu olarak tip 2 köbner fenomeni gelişen psoriasisli bir olgu. Dermatoz 2018; 9(2):1-3. (Online Article).
5. Munro K. Diagnosing and managing migraine in children and young people. Nurs Child Young People 2019; 31(1):38-47.
6. Martins LB, Teixeira AL, Domingues RB. Neurotrophins and migraine. Vitam Horm 2017; 104:459-73.
7. Charles A. The pathophysiology of migraine: Implications for clinical management. Lancet Neurol 2018; 17(2):174- 82.
8. Ansari M, Karkhaneh A, Kheirollahi A, Emamgholipour S, Rafiee MH. The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine. Acta Neurol Belg 2017; 117(3):677- 85.

9. Capo A, Affaitati G, Giamberardino MA, Amerio P. Psoriasis and migraine. J Eur Acad Dermatol Venereol 2018; 32:57-61.
10. Bolay H, Vuralli D, Goadsby PJ. Aura and Head pain: Relationship and gaps in the translational models. J Headache Pain 2019; 20(1):94.
11. Conti P, D’Ovidio C, Conti C, Gallenga CE, Lauritano D, Caraffa A, Kritas SK, Ronconi G. Progression in migraine: Role of mast cells and pro-inflammatory and anti-inflammatory cytokines. Eur J Pharmacol 2019; 844:87-94.
12. Han D. Association of serum levels of calcitonin gene- related peptide and cytokines during migraine attacks. Ann Indian Acad Neurol 2019; 22(3):277-81.
13. Yuan H, Silberstein SD. Histamine and migraine. Headache 2018; 58(1):184-93.
14. Schuster NM, Rapoport AM. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: A Review. Clin Neuropharmacol 2017; 40(4):169-74.
15. Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A, López A, Campos F, Martínez F, Castillo J, Leira R. Role of adipocytokines in the pathophysiology of migraine: A cross-sectional study. Cephalalgia 2018; 38(5):904-11.
16. Alba BK, Greaney JL, Ferguson SB, Alexander LM. Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation. Am J Physiol Heart Circ Physiol 2018; 314(2):H343-H349.
17. Sikar Aktürk A, Özdoğan HK, Bayramgürler D, Çekmen MB, Bilen N, Kıran R. Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. J Eur Acad Dermatol Venereol 2012; 26:833-7.
18. Gokhale NR, Belgaumkar VA, Pandit DP, Deshpande S, Damle DK. A study of serum nitric oxide levels in psoriasis. Indian J Dermatol Venereol Leprol 2005; 71:175-8.
19. Lukacs M, Tajti J, Fulop F, Toldi J, Edvinsson L, Vecsei L. Migraine, neurogenic inflammation, drug development - pharmacochemical aspects. Curr Med Chem 2017; 24(33):3649-65.
20. Pradhan AA, Bertels Z, Akerman S. Targeted nitric oxide synthase inhibitors for migraine. Neurotherapeutics 2018; 15(2):391-401.
21. Song J, Choi SM, Whitcomb DJ, Kim BC. Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity. Cell Death Dis 2017; 8(10):e3102.
22. Romaní J, Caixàs A, Ceperuelo-Mallafré V, Carrascosa JM, Ribera M, Rigla M, Vendrell J, Luelmo J. Circulating levels of lipocalin-2 and retinolbinding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res 2013; 305:105-12.
23. Caron A, Lee S, Elmquist JK, Gautron L. Leptin and brain-adipose crosstalks. Nat Rev Neurosci 2018; 19(3):153-65.
24. Pisanu C, Preisig M, Castelao E, Glaus J, Cunningham JL, Del Zompo M, Merikangas KR, Schiöth HB, Mwinyi J. High leptin levels are associated with migraine with aura. Cephalalgia 2017; 37(5):435-41.
25. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol 2012; 165(2):313-27.
26. Duarte H, Teixeira AL, Rocha NP, Domingues RB. Increased serum levels of adiponectin in migraine. J Neurol Sci 2014; 342(1-2):186-8.
27. Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, resistin, and adiponectin concentrations in psoriasis: A meta-analysis of observational studies. Dermatology 2017; 233(5):378-89.
28. Stjernholm T, Ommen P, Langkilde A, Johansen C, Iversen L, Rosada C, Stenderup K. Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis- like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. Exp Dermatol 2017; 26(4):338-45.
29. Owczarczyk-Saczonek A, Placek W. Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw 2017; 71(1):761-72. (Online Article).
30. Zarifoglu M, Siva A, Hayran O, Selekler K, Idiman F, Sanca Y, Irkeç C, Özmenoğlu M, Ozcan C, Tulunay C. An epidemiological study of headache in Turkey: A nationwide survey. Neurology 1998; 50:80-5.
31. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010; 2010:535918.
32. Topal IO, Degirmentepe E, Cüre K, Kızıltac U, Hökenek NB, Kocatürk E. Retrospective analysis of clinical and sociodemographic features of patients with psoriasis. Eur Arch Med Res 2017; 33:199-205.
33. Lipton RB, Scher AI, Steiner TJ, Bigal ME, Kolodner K, Liberman JN, Stewart WF. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60:441-8.
34. Egeberg A, Mallbris L, Hilmar Gislason G, Skov L, Riis Hansen P. Increased risk of migraine in patients with psoriasis: A Danish nationwide cohort study. J Am Acad Dermatol 2015; 73:829-35.